Laboratory haemostasis monitoring in COVID‐19
By J. Thachil, N. Tang, S. Gando, A. Falanga, M. Levi, C. Clark, T. Iba. Journal of Thrombosis and Haemostasis, 2020
1,565 citations recorded by the source corpus.
We thank the authors for their very useful and constructive criticisms about laboratory monitoring of haemostatic variables detailed in the ISTH guidance document for coagulopathy in COVID-19. We still believe that the use of simple and easily available laboratory markers both at admission and whilst in the hospital is necessary in the management of COVID-19 patients. Since the writing of this guidance and the letter from the experts being sent to us, there have been several reports of very high incidence of both arterial and venous thromboembolism (TE) in patients with COVID-19.1,2,3 In one report published in the Journal of Thrombosis and Haemostasis, the incidence of venous TE was 25%, some of whom died from this complication.2 Laboratory markers including D-dimer were relevant in these patients. The authors used D-dimer cut-off of 1.5 µg/mL for predicting venous TE and demonstrated sensitivity of 85.0% and specificity of 88.5% and negative predictive value of 94.7%.2 They also suggested D-dimers may be used to monitor the effectiveness of anticoagulants although this practice is not universally accepted.
Subfields: Infectious Diseases, Internal Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/62e7e05eba6b29bcb493a5389f329f056e75c88b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Coagulation abnormalities and thrombosis in patients with COVID-19 (2020, background): “5 There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients.”
- COVID-19 update: Covid-19-associated coagulopathy (2020, background): “The International Society on Thrombosis and Haemostasis published an interim guidance statement for the recognition and management of coagulopathy in Covid-19 [87].”
- Hematological findings and complications of COVID‐19 (2020, background): “Low molecular weight heparins (LMWH), or unfractionated heparin (UFH) should be preferred over direct oral anticoagulants (DOACs) due to possible drug-drug interactions with concomitant antiviral (especially anti-HIV protease inhibitors such as ritonavir) and antibacterial (such as azithromycin) tre”
- High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients (2020, neutral): “2) Male sex 20 (77) 6 (75) 14 (78) Chronic medical condition Active cancer 0 (0) 0 (0) 0 (0) Previous VTE 1 (4) 0 (0) 1 (6) Arterial hypertension 22 (85) 7 (87) 15 (83) Tobacco 7 (27) 2 (25) 5 (28) Surgery < 3 months 1 (4) 0 (0) 1 (6) Anticoagulation before admission 7 (27) 0 (0) 7 (39) .”
- Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series (2020, background): “Patients with severe COVID-19 can develop COVID-19–associated coagulopathy (CAC), with features of both disseminated intravascular coagulation and thrombotic microangiopathy, resulting in widespread microvascular thrombosis that may involve the liver (as in 1 of our patients) and consumption of coag”